BREAST CANCER

Erika P. Hamilton, MD, discusses the patient population with breast cancer enrolled in the TROPION-PanTumor01 trial in relation to the efficacy of datopotamab deruxtecan.

The final analysis of the phase 3 PANTHER study confirmed survival benefits for patients receiving dose-dense vs standard chemotherapy.

M. Michele Blackwood, MD, FACS, provided an overview of the significant advancements with personalized medicine with genomic testing in the breast cancer space.

For Breast Cancer Awareness Month, Oranus Mohammadi, MD, discussed the remarkable progress made in improving survival rates for patients with breast cancer.

Panelists discuss how ESMO 2024 presented important updates on primary end points and progression-free survival data from recent clinical studies.

Panelists discuss how updates from KEYNOTE-522 at ESMO 2024 revealed important data on overall survival and event-free survival outcomes.

Panelists discuss how the NATALEE study at ESMO 2024 presented updates on primary, secondary, and exploratory end points for evaluating a new cancer treatment.

Christos Vaklavas, MD, discusses the results of the TROPION-Breast01 trial of datopotamab deruxtecan in patients with metastatic breast cancer.

Sherry Shen, MD, discusses the GLP-1 agonists analyzed for weight change in findings from a retrospective trial of patients with breast cancer.

During a Case-Based Roundtable® event, Virginia F. Borges, MD, MMSc, discussed treatment selection for a patient with ER+, HER2 0 metastatic breast cancer and a PIK3CA mutation.

The ELECTRA trial found that the combination of elacestrant and abemaciclib was well-tolerated and showed promising clinical activity in patients with ER-positive, HER2-negative metastatic breast cancer who had previously received endocrine therapy and another CDK4/6 inhibitor.

Follow-up results from the POSITIVE trial showed that breastfeeding is achievable for patients with HR-positive breast cancer who conceived during a break from endocrine therapy.

The phase 3 HypoG-01 trial found moderately hypofractionated radiation therapy had similar lymphedema risk to standard therapy in patients with early breast cancer.

Peter Schmid, MD, PhD, discusses his key takeaways from the phase 3 KEYNOTE-522 trial and the updated findings presented at the 2024 ESMO Congress.

Superior efficacy at 12 weeks was seen with the frontline combination of abemaciclib and endocrine therapy vs standard chemotherapy in patients with advanced breast cancer.

In KEYNOTE-522, treatment with neoadjuvant pembrolizumab and chemotherapy, followed by adjuvant pembrolizumab, led to improvements in overall survival among patients with triple-negative breast cancer.

In a phase 2 trial, datopotamab deruxtecan plus durvalumab achieved a 50% overall pathologic complete response rate in patients with high-risk HER2-negative breast cancer.

Breast cancer diagnostics, therapeutics, and biomarker-driven therapy will be important focal points during the 22nd Annual School of Breast Oncology conference.

During a Case-Based Roundtable® event, Ian Krop, MD, PhD, and event participants discussed how different types of metastases and treatment toxicity would affect therapy given to patients with triple-positive breast cancer in the second article of a 2-part series.

The phase 3 study will investigate fezolinetant for vasomotor symptoms in patients receiving adjuvant endocrine therapy.

During a Case-Based Roundtable® event, Ian Krop, MD, PhD, discussed the use of chemotherapy in patients with HER2- and hormone receptor–positive metastatic breast cancer in combination with trastuzumab.

During a Case-Based Roundtable® event, Reshma Mahtani, DO, discussed the importance of data from the TROPiCS-02 and TROPION-Breast01 trials of antibody-drug conjugates in patients with hormone receptor positive metastatic breast cancer.

Yeon Hee Park, MD, discusses the unmet needs in among premenopausal patients with metastatic breast cancer.

In an interview with Targeted Oncology, Hope S. Rugo, MD, FASCO, discussed data from the ELEVATE trial of elacestrant combinations in ER-positive/HER2-negative metastatic breast cancer.